McCann FitzGerald is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma plc. Novo Nordisk will also acquire newly issued Strongbridge shares representing approximately 10% of the outstanding shares of Strongbridge in an investment of approximately $37 million. The transaction, which is expected to close in December 2018, is subject to regulatory approval.
Are you looking for someone or
something in particular?
Select how you would like to share using the options below